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Abstract
Background: Invasive lobular carcinoma (ILC) of the breast typically presents with clinical biomarkers consistent
with a favorable response to endocrine therapies, and over 90 % of ILC cases express the estrogen receptor (ER).
However, a subset of ILC cases may be resistant to endocrine therapies, suggesting that ER biology is unique in ILC.
Using ILC cell lines, we previously demonstrated that ER regulates a distinct gene expression program in ILC cells,
and we hypothesized that these ER-driven pathways modulate the endocrine response in ILC. One potential novel
pathway is via the Wnt ligand WNT4, a critical signaling molecule in mammary gland development regulated by
the progesterone receptor.
Methods: The ILC cell lines MDA-MB-134-VI, SUM44PE, and BCK4 were used to assess WNT4 gene expression and
regulation, as well as the role of WNT4 in estrogen-regulated proliferation. To assess these mechanisms in the context
of endocrine resistance, we developed novel ILC endocrine-resistant long-term estrogen-deprived (ILC-LTED) models.
ILC and ILC-LTED cell lines were used to identify upstream regulators and downstream signaling effectors of
WNT4 signaling.
Results: ILC cells co-opted WNT4 signaling by placing it under direct ER control. We observed that ER regulation of
WNT4 correlated with use of an ER binding site at the WNT4 locus, specifically in ILC cells. Further, WNT4 was
required for endocrine response in ILC cells, as WNT4 knockdown blocked estrogen-induced proliferation. ILC-
LTED cells remained dependent on WNT4 for proliferation, by either maintaining ER function and WNT4
regulation or uncoupling WNT4 from ER and upregulating WNT4 expression. In the latter case, WNT4
expression was driven by activated nuclear factor kappa-B signaling in ILC-LTED cells. In ILC and ILC-LTED
cells, WNT4 led to suppression of CDKN1A/p21, which is critical for ILC cell proliferation. CDKN1A knockdown
partially reversed the effects of WNT4 knockdown.
Conclusions: WNT4 drives a novel signaling pathway in ILC cells, with a critical role in estrogen-induced
growth that may also mediate endocrine resistance. WNT4 signaling may represent a novel target to
modulate endocrine response specifically for patients with ILC.
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Background
Invasive lobular carcinoma (ILC) represents the second
most common subtype of breast cancer, and overall it is
the sixth most common cancer diagnosis in women
in the United States [1]. ILC cases typically present with
favorable biomarkers, as >90 % of ILCs are estrogen re-
ceptor (ER)-positive and progesterone receptor (PR)-posi-
tive, <10 % are human epidermal growth factor receptor 2
(HER2)-positive, and the majority are low Ki-67-positive
[1–5]. On the basis of these biomarkers, ILCs are an
archetype of the luminal A molecular subtype, and pa-
tients with ILC may be expected to have favorable out-
comes when treated with adjuvant endocrine therapy.
However, recent retrospective analyses of the BIG 1-98
trial [6] and ABCSG-8 trial [7] suggest that, compared
with patients with similar invasive ductal carcinomas
(IDCs), a subset of patients with ILC may in fact have
poorer outcomes with endocrine therapy. Improved un-
derstanding of ER signaling, endocrine response, and the
development of endocrine resistance in ILC is critical to
improving patient outcomes.
We previously reported a study of unique ER-mediated
gene expression and signaling in ILC model systems using
gene expression microarrays coupled with ER chromatin
immunoprecipitation sequencing (ChIP-seq) [8]. In this
study, the most strongly induced ILC-specific ER target
gene was the Wnt ligand WNT4. Additionally, ChIP-seq
identified an ILC-specific estrogen receptor binding site
(ERBS) at the WNT4 locus, approximately 1.5 kb down-
stream from the WNT4 transcription start site, an evolu-
tionarily conserved region [9] that contains two predicted
estrogen response elements (EREs) (diagrammed in
Additional file 1: Figure S1). These observations suggest
that direct ER binding at this site may be responsible
for estrogen-induced WNT4 expression. Importantly,
ILC cells may be co-opting WNT4 regulation by placing
it under ER control, as Wnt4 is a transcriptional target
and downstream effector of PR signaling in the murine
adult mammary gland [10–14]. In this context, Wnt4 is
critical to maintaining a mammary progenitor cell
population (reviewed by Brisken et al. [15]). Decreased
progenitor cell potential during parity (and subsequent
parity-induced breast cancer protection) is linked to
downregulation of Wnt4 [11], but progenitor cell prolif-
eration is rescued by Wnt4 induction [16] or exogenous
WNT4 [11]. On the basis of these observations, we hy-
pothesized that WNT4 may play a critical role in
estrogen-regulated phenotypes in ILC.
To test this hypothesis, we assessed regulation and ex-
pression of WNT4, WNT4 signaling, and WNT4-medi-
ated phenotypes in ILC- and IDC-derived breast cancer
cell lines. In addition, we established a series of long-term
estrogen-deprived (LTED) endocrine-resistant variants
of the ILC cell lines MDA-MB-134-VI (MM134) and
SUM44PE (44PE), and examined the role of WNT4
in endocrine resistance in these models. Our findings
suggest that WNT4 signaling is a putative target to




MCF-7 and T47D (American Type Culture Collection
[ATCC], Manassas, VA, USA) cells were maintained as de-
scribed elsewhere [17]. MM134 (ATCC) and 44PE (Aster-
and Bioscience, Detroit, MI, USA) cells were maintained
as described previously [8]. MDA-MB-330 cells (MM330;
ATCC) were maintained as described for MM134.
HCC1428 and HT1080 cells (ATCC) were maintained in
DMEM (11965; Life Technologies, Carlsbad, CA, USA) +
10 % FBS (26140; Life Technologies). BCK4 (University of
Colorado Anschutz) was maintained as described else-
where [18]. All lines were incubated at 37 °C in 5 % CO2.
Cell lines were authenticated annually by polymerase
chain reaction (PCR)-restriction fragment length poly-
morphism analyses at the University of Pittsburgh
Cell Culture and Cytogenetics Facility and confirmed
to be mycoplasma-negative. Authenticated cells were
in continuous culture for <6 months. Cells were
hormone-deprived using charcoal-stripped FBS (CSS)
(12676, lot 1176965; Life Technologies), as described
previously [17], in phenol red-free improved mini-
mum essential medium (IMEM) + 10 % CSS (2 % CSS
for SUM44PE only). This single lot of CSS was used
for all experiments and was confirmed to have
complete hormone deprivation [19].
17β-Estradiol (E2) and 4-hydroxytamoxifen (4-OHT)
were obtained from Sigma-Aldrich (St. Louis, MO,
USA); other compounds were obtained from Tocris Bio-
sciences (Bristol, UK). E2, 4-OHT, ICI 182,780 (ICI), and
progesterone (P4) were dissolved in ethanol; RU486 (RU,
mifepristone), BMS-345541 (BMS), staurosporine (STS),
endo-IWR1 (IWR), and JW 67 (JW) were dissolved in di-
methyl sulfoxide.
Proliferation and viability assays
For cellular proliferation assays, we used the FluoRe-
porter double-stranded DNA quantitation kit (F2692;
Life Technologies) according to the manufacturer’s in-
structions. Cell death was assessed using CellTox
Green (G8741; Promega, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. For each assay,
cells were plated in 96-well plates and allowed to at-
tach overnight prior to the indicated treatments.
Fluorescence was assessed using a VICTOR X4 plate
reader (PerkinElmer, Waltham, MA, USA). For assays,
points and/or bars represent the mean of five or six
biological replicates ± SD.
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RNA interference
Small interfering RNAs (siRNAs) were reverse-transfected
using Lipofectamine RNAiMAX reagent (Life Technolo-
gies) according to the manufacturer’s instructions. A list
of constructs used in this study is available in Additional
file 2. Notably, the efficacy of WNT4 knockdown varied
across commercially available constructs. The extent of
knockdown correlated with effects on growth (Additional
file 3: Figure S2). The reagent indicated (Additional file 2)
outperformed other reagents tested (additional details
available on request).
Gene expression analyses
For RNA extractions, we used the illustra RNAspin Mini
Kit (GE Healthcare Life Sciences, Little Chalfont, UK) or
the RNeasy Mini Kit (QIAGEN, Hilden, Germany). For
complementary DNA conversion, we used iScript master
mix (Bio-Rad Laboratories, Hercules, CA, USA), and for
quantitative PCR (qPCR) reactions, we used SsoAd-
vanced SYBR Green Master Mix (Bio-Rad Laboratories)
on a CFX384 thermocycler (Bio-Rad Laboratories), ac-
cording to the manufacturer’s instructions. Expression
data were normalized to RPLP0. Primer sequences are
available in Additional file 2.
Chromatin immunoprecipitation
Cells were hormone-deprived as described above prior
to treatment with 0.1 % EtOH, 1 nM E2, 1 μM ICI, 100
nM P4, or 1 μM RU486 for 45 minutes. ChIP experi-
ments were performed as described previously [20] with
minor modifications:
1. Nuclei were extracted prior to sonication by
resuspending the fixed cell pellet in nuclei
preparation buffer (5 mM 1,4-
piperazinediethanesulfonic acid (PIPES), 85 mM KCl
[pH 8.0] + 0.5 % Nonidet P-40 + protease inhibitor)
with rotation at 4 °C for 30 minutes. Nuclei were then
pelleted and lysed and/or sonicated as described.
2. SDS was omitted from buffers Tris-sucrose-
ethylenediaminetetraacetic acid I (TSEI) and TSEII.
3. Carrier molecules were added during
immunoprecipitation [21].
In immunoprecipitation experiments, we used ERα
(HC-20) and rabbit immunoglobulin G (sc2027) anti-
bodies (Santa Cruz Biotechnologies, Dallas, TX, USA).
PCR was performed as described above, normalized
to percentage input. Primer sequences are available in
Additional file 2.
Long-term estrogen deprivation
Endocrine-resistant variants of MM134 and 44PE were
generated by maintaining cells in hormone-deprived
conditions using IMEM+ 10 % CSS. As 44PE cells are only
modestly hormone-responsive and their basal medium has
minimal hormone content, we first subderived cells in fully
hormone-replete conditions by maintaining SUM44PE as
described for MM134 (DMEM/L-15 + 10 % FBS) for
3 months. The resulting variant, termed SUM44/F, has an
increased proliferative response to E2 (Additional file 4:
Figure S3). To generate ILC-LTED lines, MM134 and
SUM44/F were hormone-deprived as described above and
subsequently plated in a 6-well plate. Each well was main-
tained independently over 6–12 months until cells could
be passaged routinely; this generated four LTED MM134
and two LTED SUM44/F lines.
Immunoblotting
SDS-PAGE was performed using standard methods. Pro-
teins were transferred to polyvinylidene difluoride (PVDF)
membranes for Western blot analysis using chemilumines-
cence detection. Antibodies were used according to the
manufacturers’ recommendations: ERα (clone 6 F11; Leica
Biosystems, Buffalo Grove, IL, USA), p65 (8242; Cell Sig-
naling Technology, Danvers, MA, USA), phospho-p65
(serine 536, CS 3033; Cell Signaling Technology), RelB (CS
4922; Cell Signaling Technology), c-Rel (CS 4727; Cell
Signaling Technology), NFKB1 (p105/p50, CS 12540; Cell
Signaling Technology), p21 (CS 2946; Cell Signaling Tech-
nology), DVL2 (CS 3216; Cell Signaling Technology),
DVL3 (CS 3218; Cell Signaling Technology), and
tubulin (T9026; Sigma-Aldrich).
Transcription factor response element reporter assays
A targeted screen for transcription factor activity was
performed using the Cignal 45-Pathway Reporter Array
System (QIAGEN). Plasmids were reverse-transfected
using Attractene (QIAGEN). The following day, cells were
treated with 0.01 % EtOH or 100 nM ICI. All conditions
were performed in biological triplicate. Cells were assayed
for reporter activity 42 h posttreatment using the Dual-
Luciferase Reporter Assay System (Promega).
For canonical Wnt signaling reporter assays, we used
TOP and Renilla plasmids, a kind gift from the Monga
laboratory (University of Pittsburgh). Wnt expression
plasmids were obtained from the Open Source Wnt Pro-
ject (Addgene, Cambridge, MA, USA). The plasmid kit
was a gift from Marian Waterman, David Virshup, and Xi
He (kit 1000000022; Addgene). Plasmids were cotrans-
fected using Lipofectamine LTX and PLUS reagent (Life
Technologies). Cells were assayed for reporter activity
24 h posttransfection using the Promega Dual-Luciferase
Reporter Assay System.
Statistical analyses
Curve-fitting and statistical analyses for in vitro studies
were performed using Prism version 5.04 software
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(GraphPad Software, La Jolla, CA, USA). For in silico
analyses, we used expression values derived from The
Cancer Genome Atlas (TCGA) [22] breast cancer cases
and normal tissue (in units of transcripts per million)
downloaded from the Gene Expression Omnibus data-
base [GEO:GSE62944] [23]. PAM50 subtypes for the
TCGA tumors were defined using the “genefu” package in
R (version 2.4.2). Briefly, 50:50 distributions of ER+/ER−
tumors were sampled for the median centering step, and
subtypes were assigned to all tumors. This process
was repeated 100 times, and the consensus subtype
for each tumor was taken. Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC)
[24] data were downloaded from the Synapse software
platform (syn1688369; Sage Bionetworks, Seattle, WA,
USA). Microarray probes were selected for individual
genes based on the probe set with the highest inter-
quartile range.
Results
WNT4 is necessary for ILC cell proliferation in culture
To determine whether WNT4 is necessary for breast
cancer cell proliferation, we used siRNA to knock down
WNT4 expression in breast cancer cell lines (BCCLs).
WNT4 knockdown was performed in the ILC cell lines
MDA-MB-134-VI (MM134) and SUM44PE (44PE) and
compared with IDC cell lines MCF-7 and HCC1428.
Notably, MCF-7 cells expressed more than tenfold less
WNT4 than ILC lines, while HCC1428 was the only ER-
positive BCCL with higher WNT4 expression than
MM134 [25, 26]; this was confirmed by qPCR (Fig. 1a).
In all four BCCLs, siRNA targeting WNT4 (siWNT4)
produced about 90 % knockdown (Fig. 1a). siWNT4
suppressed the growth of both MM134 and 44PE cells
(by approximately 60 % and 40 %, respectively) (Fig. 1b).
However, growth suppression was not observed in MCF-
7 or HCC1428 (Fig. 1b).
We further assessed whether WNT4 was specifically
necessary for estrogen-induced growth. The growth of
MM134 plus E2 was completely suppressed by either of
two individual siWNT4 constructs. Growth was equiva-
lent to the absence of estrogen (Fig. 1c). This was also
observed in SUM44/F (a 44PE variant with increased
endocrine response; see the Methods section above and
Additional file 4: Figure S3), but siWNT4 had no effect
on estrogen-induced growth in MCF-7 (Fig. 1d). Import-
antly, the effect of siWNT4 on cell growth is likely im-
mediately due to an inhibition of proliferation, as cell
death following siWNT4 was not observed until more
than 3 days post-WNT4 knockdown (Fig. 1e). These data
suggest that WNT4 may be required for the prolifera-
tion of ILC cells but not IDC cells, and that estrogen-
induced proliferation in ILC cells requires WNT4.
Estrogen regulates WNT4 expression via ER binding at
the WNT4 ERBS
On the basis of potential roles for both ER and PR in
regulating WNT4 expression, we used a series of ER-
positive ILC (MM134, 44PE, BCK4) and IDC (MCF-7,
T47D) BCCLs to further investigate WNT4 regulation.
Expression of WNT4 in response to combinations of E2,
P4, and antihormones was compared with GREB1 (ER
target gene) and FKBP5 (PR target gene). As shown in
Fig. 2a, GREB1 expression was induced by E2 and re-
versed by ICI in all lines, whereas FKBP5 was only P4-
induced in the strongly PR-positive lines T47D and
BCK4. Other BCCLs tested were PR-weak or negative.
These experiments confirmed that WNT4 expression
was solely ER-regulated in MM134 and 44PE; P4 and
the PR antagonist RU486 had no effect, whereas WNT4
expression was E2-induced and ICI-reversed. In BCK4,
neither E2 nor P4 induced WNT4. We also observed
ER regulation of WNT4 in the ILC cell line MM330
(Additional file 5: Figure S4a), which we recently
characterized as having functional ER signaling (M. J.
Sikora et al., unpublished data). In contrast, IDC cells
maintained complete or partial PR control of WNT4 ex-
pression.WNT4 was weakly E2-induced in MCF-7, but P4
and/or RU cotreatment reduced expression, suggesting
that WNT4 may be ER/PR-coregulated in MCF-7. In
T47D, WNT4 expression was solely PR-regulated, as P4
induced expression but E2 had no effect. Thus, IDC cells
may maintain WNT4 under complete or partial PR con-
trol, similarly to the normal adult mammary gland,
whereas some ILCs switch WNT4 from PR to ER
regulation.
Interestingly, though we detected ER regulation of
WNT4 in MCF-7 in qPCR-based analysis, this was not
observed in our prior microarray analyses [8]. In retro-
spect, WNT4 expression values failed to pass minimum
microarray signal thresholds in the public datasets used.
Consistent with this, overall WNT4 expression was very
low in IDC vs ILC lines (Fig. 2b).
Using ChIP-qPCR, we then assessed whether WNT4
regulation by the ER correlated with ER binding at the
WNT4 ERBS (Additional file 1: Figure S1) (Fig. 2c). As a
control, we assessed ER binding at a canonical ERBS at
IGFBP4, and we found that E2 induced strong ER binding
in all five BCCLs, consistent with activation of canonical
ER-mediated transcription. However, E2 induced binding
at WNT4 only in ILC cells with ER-specific regulation of
WNT4, namely MM134 and 44PE. This is consistent with
the hypothesis that ER directly regulates WNT4 expres-
sion via ER binding at the WNT4 ERBS in ILC cells.
Recently, Mohammed et al. reported a functional ER-
PR interaction that modified genomic binding in breast
cancer cell lines [27]. As ER and PR may interact to
regulate WNT4 in MCF-7 cells (Fig. 2a), we investigated
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the ChIP-seq data reported by Mohammed et al. These
data identified weak, inconsistent ER binding at the
WNT4 ERBS and a P4-induced ER binding site about
30 kb upstream from WNT4 in MCF-7 cells (Additional
file 5: Figure S4b). We assessed ER binding at these loci
with E2 with or without P4, and we did not detect P4-
induced changes in ER binding at IGFBP4 or WNT4.
Additionally, we did not detect binding at the upstream
site (Additional file 5: Figure S4c). These data do not
identify a direct link between P4-induced changes in ER
binding and changes in WNT4 regulation.
Endocrine-resistant ILC cell lines upregulate WNT4 or
maintain ER regulation of WNT4
We hypothesized that because WNT4 plays a critical
role in estrogen-induced proliferation in ILC, it may play
a similar role in endocrine resistance. To model endo-
crine resistance during aromatase inhibitor therapy in
ILC, we generated LTED variants of MM134 (134:L/A,
L/B, L/D, and L/E; collectively referred to as 134:LTED)
and 44PE (44:L/A and L/B; collectively referred to as
44:LTED) (Additional file 6: Figure S5a). All LTED lines
remained ER-positive, as determined by immunoblot
Fig. 1 WNT4 is necessary for estrogen-induced growth in invasive lobular carcinoma (ILC) cells. a Breast cancer cell lines (BCCLs) were reverse-
transfected with 10 nM siWNT4 or siSCR (Scrambled siRNA control) pools. WNT4 expression was assessed by quantitative polymerase chain
reaction. Bars represent mean of biological triplicate ± SD. p < 0.05 for each siSCR vs siWNT4 (t test). b BCCLs were transfected as in (a) with
increasing concentrations of small interfering RNA (siRNA), and proliferation was assessed 6 days posttransfection. siWNT4-treated cell proliferation
was normalized to siSCR of equivalent concentration. *p < 0.01 by analysis of variance (ANOVA) of siRNA effect (siSCR vs siWNT4). c MDA-MB-134-VI
(MM134) cells were hormone-deprived and reverse-transfected with siSCR or individual siWNT4 constructs. Cells were then treated with 100 pM
17β-estradiol (E2) or 0.01 % EtOH approximately 16 h posttransfection, and proliferation was assessed at the indicated time posttreatment.
*,p < 0.0001 by ANOVA of E2 effect (siSCR without E2 vs with E2). x p = n.s. by ANOVA of E2 effect (siSCR without E2 vs either siWNT4). d Cells were
treated as in (c), and proliferation was assessed 6 days posttreatment. *p < 0.05 for condition with E2 siSCR vs siWNT4 (t test). n.s. Not significant.
e BCCLs were reverse-transfected with 10 nM siWNT4 or siSCR. The following day (after approximately 16 h), cells were treated with CellTox Green dye
and 1 μM ICI 182,780 (fulvestrant; ICI) or staurosporine (STS) as indicated. Increased fluorescence represents accumulation of nonviable cells. Time
points represent repeated measures of the same initial cell populations. *p < 0.05 by two-way ANOVA vs control, treatment effect. IDC Invasive ductal
carcinoma, 44PE SUM44PE cell line
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analysis. Each of the 134:LTED lines had reduced ER vs
parental cells, whereas both 44:LTED lines had increased
ER vs 44PE and SUM44/F (Additional file 6: Figure S5b).
Despite retaining ER expression, 134:LTED lines were no
longer endocrine-responsive. Neither E2 nor 4-OHT in-
duced proliferation, and ICI had no effect in any
134:LTED line (Additional file 6: Figure S5c). Conversely,
though E2 did not induce proliferation in the 44:LTED
lines, each was growth-inhibited by both 4-OHT and
ICI, suggesting that ER activation is maintained in
44:LTED cells despite the absence of exogenous steroid
hormones (Additional file 6: Figure S5c).
We next examined expression and ER regulation of
WNT4 in ILC-LTED cells. Each 134:LTED cell line
upregulated WNT4 vs parental MM134 cells in
hormone-replete conditions (Fig. 3a, top), but ICI treat-
ment did not affect expression in any 134:LTED line.
Conversely, 44:LTED had decreased WNT4 expression
vs 44PE; however, expression was reduced by ICI in
44:LTED. This suggests that ER regulation of WNT4 is
maintained in 44:LTED despite hormone deprivation.
Estrogen regulation of WNT4 was paralleled by similar
observations with IGFBP4 (Fig. 3a, bottom) and GREB1
(Additional file 7: Figure S6a). ICI had no effect on
IGFBP4 or GREB1 expression in 134:LTED, but it re-
duced their expression in 44:LTED. These data parallel
the proliferative endocrine responses described above
(Additional file 6: Figure S5c). Taken together, WNT4
Fig. 2 Estrogen regulation of WNT4 correlates with estrogen receptor (ER) binding at the WNT4 estrogen receptor binding site (ERBS). a Breast
cancer cell lines (BCCLs) were hormone-deprived and treated in biological triplicate with vehicle (0.2 % EtOH), 1 nM 17β-estradiol (E2), 100 nM
progesterone (P4), 1 μM ICI 182,780 (fulvestrant; ICI), or 1 μM RU486 (RU), as indicated. RNA was harvested 24 h posttreatment. Bars represent
mean ± SD as fold change vs vehicle control; red error bars indicate analysis of variance (Dunnett’s multiple comparisons test) vs vehicle control
(p < 0.05). b Data from (a) were normalized to a pan-average of all samples across BCCLs tested. c BCCLs were hormone-deprived and treated as
indicated for 45 minutes. Chromatin immunoprecipitation (ChIP) was performed as described in the Methods section. Red values indicate fold
enrichment for E2 vs vehicle in ER ChIP. The data were derived from a single experiment but are representative of two or three experiments.
SUM44 SUM44PE cell line, HR Hormone receptor, IDC Invasive ductal carcinoma, IgG Immunoglobulin G, ILC Invasive lobular carcinoma, PR
Progesterone receptor
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upregulation independent of ER, or maintenance of ER
control of WNT4, is a shared feature across this series of
six endocrine-resistant ILC lines.
We then assessed ER binding at the WNT4 ERBS,
based on the changes in WNT4 expression and regulation
in ILC-LTED cells. Shown in Fig. 3b (top), consistent with
the loss of ER regulation of WNT4, we observed minimal
or no ER binding at this locus in 134:LTED. However,
strong ER binding was observed at the WNT4 ERBS
in 44:LTED, paralleling maintained ER regulation. This
binding could be ablated with ICI. Similar results were ob-
served at the IGFBP4 ERBS (Fig. 3b, bottom). These re-
sults are consistent with the hypothesis that ER binding at
the WNT4 ERBS is required for ER regulation of WNT4,
as the 44:LTED lines maintained ER binding at this site,
whereas the 134:LTED lines had uncoupled WNT4 from
the ER and no longer used the WNT4 ERBS.
WNT4 is critical for proliferation in LTED models
The maintenance of WNT4 expression or regulation
in the LTED phenotype suggests that ILC-LTED cells
may remain dependent on WNT4 signaling. To test
this, we used siRNA as described above to knock down
WNT4. The 134:LTED lines remained growth-inhibited
by siWNT4, but the siWNT4 was less effective in sup-
pressing growth than in the parental MM134 cells
(Fig. 4a, top). 134:L/E was most sensitive, with growth
suppressed about 40 %. However, unlike 134:LTED,
44:LTED cells were completely resistant to siWNT4
relative to 44PE (Fig. 4a, bottom). This correlates
with the increased WNT4 expression in 134:LTED but de-
creased expression in 44:LTED (Fig. 3). Because 44:LTED
displayed maintained ER activity and WNT4 regulation,
we hypothesized that siWNT4 combined with ICI may
potentiate growth suppression. As shown in Fig. 4b (top),
siWNT4 alone inhibited proliferation of 134:L/E, but ICI
treatment had no effect, consistent with lack of endocrine
response. Conversely, 44:L/A was resistant to siWNT4,
but growth was modestly inhibited by ICI alone. Combin-
ing siWNT4 with ICI increased growth suppression
beyond either treatment alone (Fig. 4b, bottom). We also
examined combining siWNT4 with fibroblast growth
factor receptor (FGFR) inhibition, as parental ILC cells
are codependent on ER and FGFR1 [8]. ILC-LTED cells
remained sensitive to the FGFR inhibitor PD173074, but
the relative effect was equivalent with or without siWNT4
(Additional file 7: Figure S6b), suggesting that additional
signaling pathways were activated during LTED to
maintain viability. Thus, ILC-LTED cells require WNT4
to maintain proliferation, but the context of this de-
pendence is based on the endocrine responsiveness of
the cells targeted.
Fig. 3 Expression and regulation of WNT4 in invasive lobular carcinoma endocrine-resistant long-term estrogen-deprived (ILC-LTED) cells correlates
with use of the WNT4 estrogen receptor binding site (ERBS). a Breast cancer cell lines (BCCLs) in their respective standard conditions were treated in
biological triplicate with 0.1 % EtOH or 1 μM ICI 182,780 (fulvestrant; ICI). RNA was harvested 24 h posttreatment. Bars represent mean ± SD. *p < 0.05
for vehicle control vs ICI (t test). b BCCLs were treated as in (a) for 60 minutes. Chromatin immunoprecipitation (ChIP) was performed as described in
the Methods section. Data derived from single experiment, but are representative of duplicate experiments. “E2 status” denotes the hormone status of
the experimental culture medium. +FBS-containing medium; −Charcoal-stripped FBS-containing medium. qPCR Quantitative polymerase chain reaction,
E2 17β-Estradiol, MM134 MDA-MB-134-VI, SUM44 SUM44PE cell line
Sikora et al. Breast Cancer Research  (2016) 18:92 Page 7 of 16
Activated nuclear factor kappa-B in LTED models regu-
lates WNT4-CDKN1A/p21 pathway
A defining feature of ILC is E-cadherin loss associated with
dysfunction or loss of catenin proteins (e.g., β-catenin
loss in ILC vs IDC [28]; Additional file 8: Figure S7a).
Additionally, though WNT4 can activate β-catenin in
some contexts, it is typically considered a noncanonical
Wnt ligand [29, 30]. Coupled with the lack of β-catenin
protein in ILC [31, 32], it is unlikely that WNT4 can acti-
vate canonical, β-catenin-dependent Wnt signaling in ILC
cells. We confirmed this using the TOPFlash reporter in
MM134 cells (Additional file 8: Figure S7b). No TOPFlash
activity was detected in MM134; cotransfection with
WNT1, WNT3A, or WNT4 could not induce activity.
WNT1 and WNT3A activated β-catenin-dependent tran-
scription in HT1080 cells; WNT4 did not, despite indu-
cing phosphorylation of the DVL2/3 Wnt signaling
molecules in HT1080 (Additional file 8: Figure S7c) [33].
These observations suggest that WNT4 is acting via a β-
catenin-independent mechanism in ILC cells.
To identify putative noncanonical pathways regulating
or executing WNT4 signaling, we assessed the activity
of 45 transcription factors in ILC vs ILC-LTED (parental
vs 134:L/E or 44:L/A) in the presence or absence of ICI
(Fig. 5a and Additional file 9: Figure S8). The ERE re-
porter confirmed our observations regarding endocrine
response in ILC-LTED; ER activity was ablated in 134:L/E
and was maintained but ICI-sensitive in 44:L/A. Among
the remaining 44 reporters, two were upregulated in both
ILC-LTED lines with and without ICI, nuclear factor
kB (NF-kB), and Oct-4 (Fig. 5a). Oct-4 signaling was most
strongly activated in 44:L/A but became ICI-sensitive
in those cells. NF-kB activity was ICI-resistant and
upregulated approximately seven- to tenfold in ILC-
LTEDs vs parental cells. As NF-kB has previously been
implicated in endocrine resistance (see Discussion section
below), we further examined NF-kB signaling. Consistent
with increased NF-kB activity, immunoblotting showed
increased phospho-p65 and increased active NFKB1 (p50)
in each ILC-LTED; notably, 134:L/E also showed increased
levels of both RelB and c-Rel compared with MM134
(Fig. 5b). Increased NF-kB activity in ILC-LTED also cor-
related with increased sensitivity to inhibitor of NF-kB
BMS vs parental cells (Additional file 10: Figure S9a).
These observations demonstrate that NF-kB signaling is a
critical pathway in these ILC-LTED models.
We next investigated whether NF-kB signaling is an
effector or regulator of WNT4 signaling. In support of
the latter, we identified two putative NF-kB/Rel binding
sites [34, 35] at the WNT4 ERBS (Additional file 10:
Figure S9b). Taken together with our WNT4 expression
and regulation data, we hypothesized that NF-kB signaling
might be an upstream regulator responsible for the ER-
independent WNT4 upregulation in 134:LTED. To test
Fig. 4 WNT4 dependence in invasive lobular carcinoma endocrine-resistant long-term estrogen-deprived cells (ILC-LTED) cells is linked to
endocrine response context. a Breast cancer cell lines were reverse-transfected with increasing concentrations of siWNT4 or 12.5 nM siSCR, or were
mock-transfected (Ctrl). Growth was assessed 6 days posttransfection. siSCR was toxic in 134:L/A and 44:L/B, and these lines were not
included in analyses or future small interfering RNA (siRNA) experiments. b Cells were reverse transfected with 35 nM siRNA and treated
with increasing concentrations of ICI 182,780 (fulvestrant; ICI) approximately 16 h posttransfection. Growth was assessed 6 days posttreatment.
*p < 0.05; bottom of nonlinear regression for siSCR vs siWNT4. 44PE SUM44PE cell line, MM134 MDA-MB-134-VI
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this hypothesis, we knocked down NF-kB pathway com-
ponents and assessed WNT4 expression. In 134:L/E,
knockdown of TNF, TNFSF10 (TRAIL), NFKB2, and BCL3
had no effect on WNT4 expression (Additional file 10:
Figure S9c, left); knockdown of REL, RELA, and RELB
modestly suppressed WNT4 expression without reaching
statistical significance (Additional file 10: Figure S9c,
right), potentially due to compensation among individual
Rel proteins. However, targeting NFKB1 (siNFKB1)
produced approximately 50 % suppression of WNT4
expression in 134:L/E, and this was not observed in
44:L/A (Fig. 5c). The converse of this observation was
not true; siWNT4 did not affect phosphorylation of
p65 or activation of p100 to p52 (Fig. 5d), nor did it
affect expression of NF-kB target genes (Fig. 5e).
These data suggest that though activated NF-kB was ob-
served in both 134:LTED and 44:LTED, NF-kB signaling
specifically regulated WNT4 expression when WNT4 was
uncoupled from the ER (134:LTED), acting upstream to
driveWNT4 expression.
In examining putative NF-kB target genes, we found
that CDKN1A (p21WAF1/CIP1) was strongly suppressed in
ILC-LTED vs parental cells, and that siWNT4 induced
CDKN1A (Fig. 6a). Increased CDKN1A correlated with
increased p21 protein (Fig. 6b). Regulation of CDKN1A
was not observed in MM134 cells following treatment
with β-catenin inhibitors (Additional file 10: Figure S9d),
suggesting that WNT4 regulation of CDKN1A is not β-
catenin-dependent. The fold increase in CDKN1A upon
siWNT4 was highest in cells that were growth-inhibited
by siWNT4, specifically ILC vs IDC (Additional file 10:
Figure S9e). This suggests that WNT4 suppresses
CDKN1A and that the increase in CDKN1A/p21 upon
WNT4 knockdown leads to the inhibition of prolifera-
tion. To test this hypothesis, we combined siWNT4
with siCDKN1A to reverse the effects of siWNT4. As
Fig. 5 Activated nuclear factor kB (NF-kB) in invasive lobular carcinoma endocrine-resistant long-term estrogen-deprived (ILC-LTED) cells drives
WNT4 expression. a Transcription factor reporter arrays were performed as described in the Methods section. Data are expressed as relative luciferase
units (RLU) normalized to RLU from a negative control (luciferase without a response element). *p < 0.05; n.s., not significant (t test). Statistical tests were
not corrected for multiple comparisons in this experiment, owing to the hypothesis-generating nature of this semibiased screen. b Breast cancer cell
lines (BCCLs) were maintained in their respective standard conditions. Immunoblotting was performed as described in the Methods section. c BCCLs
were reverse transfected with 10 nM small interfering (siRNA), and RNA was collected 60 h posttransfection. Bars represent the mean of biological
triplicate ± SD. *p < 0.05 by analysis of variance of expression vs siSCR (Dunnett’s multiple comparisons test). d and e BCCLs were reverse-transfected
with 10 nM siRNA, and lysates and/or RNA were collected 48 h posttransfection. d Immunoblotting was performed as described in the Methods
section. Images are representative of duplicate experiments. e Gene expression data are shown as means of biological triplicate ± SD. p = not
significant for siSCR vs siWNT4 (t test). ER Estrogen receptor, 44PE SUM44PE cell line, MM134 MDA-MB-134-VI
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Fig. 6 siWNT4-mediated growth suppression is mediated by increased CDKN1A/p21. a Breast cancer cell lines (BCCLs) were reverse-transfected
with 10 nM small interfering RNA (siRNA), and RNA was collected 48 h posttransfection. Gene expression data are shown as the mean of biological
triplicate ± SD. p < 0.05 for each SCR vs WNT4 (t test). b Left, SUM44PE (44PE) cells were reverse-transfected with 10 nM siRNA, and lysates
were collected 48 h posttransfection. The samples presented were also used in Fig. 5d, and the loading control is replicated for clarity. Data
are representative of duplicate experiments. Right, MDA-MB-134-VI (MM134) cells were reverse-transfected with 10 nM siRNA (20 nM total
for combinations), and lysates were collected 48 h posttransfection. 1, GE Dharmacon siGENOME control pool 2; 2, Sigma-Aldrich MISSION control pool
1. Reduction in p21 protein levels with scrambled control siRNA was a class effect across all commercial scrambled siRNA pools tested, observed only
in MM134 cells. c Left, 44PE cells were reverse-transfected with increasing concentrations of siWNT4 in the presence of 10 nM siSCR or siCDKN1A.
Proliferation was assessed 7 days posttransfection. Data are shown as fold change vs siSCR or siCDKN1A control (no siWNT4). p < 0.01 by analysis of
variance (ANOVA) for interaction (siSCR vs siCDKN1A on siWNT4 effect). Right, MM134 cells were reverse-transfected with 10 nM siRNA as indicated.
Proliferation was assessed 7 days posttransfection. Data are shown as fold change vs mock transfection. *p < 0.05 by ANOVA (Dunnett’s
multiple comparisons test) vs siWNT4 alone. n.s. Not significant. d Schematic of WNT4 regulation and signaling in invasive lobular carcinoma (ILC) and
ILC endocrine-resistant long-term estrogen-deprived (ILC-LTED) cells. Red stars, WNT4 estrogen receptor binding site. Left, in parental ILC
cells, 17β-estradiol (E2) activates the estrogen receptor (ER), which binds at WNT4 and drives WNT4 expression. Center, in 134:LTED, the ER no longer
binds at WNT4, and activated nuclear factor kB (NF-kB) drives increased WNT4 expression. Right, In 44:LTED, the ER binds at WNT4 despite the absence
of exogenous ligands and, potentially in coordination with Oct-4, maintains weaker WNT4 expression. Bottom, WNT4 initiates a Wnt signaling pathway
that is likely β-catenin-independent. This leads to suppression of CDKN1A expression and a decrease in p21 protein, which relieves p21-mediated
growth inhibition and permits cell growth.
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shown in Fig. 6c, concurrent knockdown of CDKN1A
and WNT4 partially reversed siWNT4-mediated growth
inhibition in both 44PE and MM134. On the basis of
these observations, suppression of CDKN1A may be a
critical component of WNT4 signaling in ILC (Fig. 6d).
This pathway may be activated by NF-kB signaling
during the development of endocrine resistance to
maintain WNT4 expression, CDKN1A suppression, and
cell proliferation.
WNT4 expression is increased in luminal breast tumors
We used public datasets from The Cancer Genome
Atlas [22] and the METABRIC study [24] to assess
WNT4 expression and associations with clinical and mo-
lecular features in breast tumors. WNT4 expression is in-
creased in ER-positive vs ER-negative tumors overall, and
is highest in the luminal A subtype (Fig. 7a). Interestingly,
WNT4 expression was also increased in normal-like tu-
mors and adjacent normal breast tissue vs the basal and
HER2 subtypes, consistent with the role of WNT4 in nor-
mal breast physiology. Across ER-positive breast tumors,
WNT4 expression was higher in ILC than in IDC, but this
may be due to the increased proportion of luminal A tu-
mors among ILCs (Fig. 7b) [3].WNT4 expression was also
increased in PR-positive tumors vs PR-negative tumors
among all ER-positive tumors and ER-positive IDCs
(Fig. 7c). A similar trend was observed in ER-positive ILCs
despite the limited number of PR-negative ILCs. Consist-
ent with increased WNT4 expression in luminal A/PR-
positive tumors, high WNT4 expression is associated with
improved disease-specific survival among all ER-positive
tumors and ER-positive IDCs (Fig. 7d).
Discussion
ILCs typically present with clinical biomarkers consistent
with endocrine responsiveness, and nearly all patients
with ILC are treated with adjuvant endocrine therapy
[1, 36]. However, recent retrospective clinical trial data
suggest that at least a subset of patients with ILC may
have poor outcomes with endocrine therapy [6, 7], sug-
gesting that, compared with IDC, ER biology and signaling
may be unique in ILC cells. Consistent with this, our re-
port on endocrine response in ILC model systems demon-
strated that ER signals via unique transcriptional targets in
ILC cells [8], which we hypothesized would mediate endo-
crine response in ILC. We identified the Wnt ligand
WNT4 as a putative novel effector of ER signaling specif-
ically in ILC cells, and we demonstrate in the present
study that WNT4 is a driver of endocrine response and
resistance in ILC (Fig. 6d).
In the murine mammary gland, Wnt4 is critical in
pregnancy-induced ductal elongation and branching
[10], as well as in maintenance of the progenitor cell
niche [11–13]. In these contexts, WNT4 serves as an
effector of PR signaling and is directly regulated by P4/
PR. We observed PR regulation of WNT4 in the PR-
positive BCCL T47D (Fig. 2a), but elucidating the mech-
anism that places WNT4 under ER control in ILC is an
important future direction for research. Interestingly, the
EREs at the WNT4 ERBS are canonical half-EREs but
deviate from the consensus full-ERE sequence (Add-
itional file 1: Figure S1); thus, a specific transcription fac-
tor context may be required to access and/or use this site
in ILC. Interestingly, potential ILC-specific modifiers of
ER function were reported in recent large-scale genomic
studies in which researchers identified differential expres-
sion and mutation of FOXA1 vs GATA3 [3] and amplifica-
tion of ESR1 [5]. However, we have not detected these
aberrations in MM134 or 44PE (T. Du, K. Levine, M. J.
Sikora, et al., unpublished manuscript; also see [22]), and
thus WNT4 regulation is likely mediated by other factors.
Putative factors from murine tissues where Wnt4 is
hormone-regulated include Foxo1 [37], Foxc2 [38], Wt1
[39, 40], Mta3 [41], MED1 [42], and Egr1 [43]. Another
putative cofactor may be YAP and/or TAZ, which cross-
talk with both canonical and noncanonical Wnt signaling
[44, 45]; nuclear (active) YAP is elevated in ILC tumors
[46]. Finally, the activation of Oct-4 observed in ILC-
LTED (Fig. 5a) paralleled WNT4 expression in ILC-LTED
cells (i.e., ICI sensitivity in 44:LTED), and thus Oct-4 may
play a role in maintaining ER regulation of WNT4 in
44:LTED. Oct-4 may also connect differentiation or pro-
genitor state toWNT4 regulation. Perhaps consistent with
this, Wnt4 in the pubertal murine mammary gland is in
fact modestly E2-induced, but it is strictly P4-induced in
the adult gland [14]. Though these observations are intri-
guing, the Oct-4 response element used is likely promis-
cuous across Oct/POU family members, and thus Oct
signaling in ILC-LTED may be tied to a number of related
transcription factors, though Oct-4 itself has recently been
implicated in endocrine resistance [47].
Noncanonical Wnt4 signaling pathways have been
examined in murine tissues but are greatly context-
dependent. β-Catenin-independent WNT4 signaling has
not been extensively characterized in the breast or in
breast cancer. In ILC cells, we identified CDKN1A/p21 as
a novel WNT4 signaling target and demonstrated that
CDKN1A/p21 regulation is a critical component of
WNT4-mediated growth (Fig. 6). p21 has previously been
shown as a direct transcriptional repressor of Wnt4 [48],
but we observed the converse, that WNT4 is an upstream
regulator of CDKN1A. Though our transcription factor
screen did not identify a putative effector of WNT4 to
suppress CDKN1A, a number of factors and/or pathways
have been reported downstream of Wnt4 in murine tis-
sues and thus may be functioning in ILC, including p38/
Jnk [49], SF-1(NR5A1) [50, 51], EAF1 and EAF2 [52, 53],
Runx-1 [54], and Fst [55]. Yu et al. also demonstrated that
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noncanonical Wnt4 signaling could block ovariectomy-
induced osteoporosis via inhibition of receptor activator
of nuclear factor kB ligand-induced NF-kB signaling [56]
(though we did not observe changes in NF-kB signaling
upon siWNT4 in ILC-LTED; Fig. 5d and e). Additionally,
Wnt4 regulates steroidogenesis in ovarian and adrenal
models [57–59], which may have significant implications
should this also be true in ILC. However, WNT4 signaling
Fig. 7 WNT4 expression is increased in hormone receptor-positive and luminal breast tumors. Source data are described in the Methods section.
a Left, p value by Mann-Whitney U test for estrogen receptor (ER)-negative vs ER-positive breast tumors. Right, Categories represent PAM50 molecular
subtypes. AdjNor Adjacent normal breast tissue. p Values by Tukey’s test for pairwise comparisons; n.s. Not significant (p > 0.05). b and (c) p Values by
Mann-Whitney U tests for invasive ductal carcinoma (IDC) vs invasive lobular carcinoma (ILC) in each subset of breast tumors. d WNT4 expression
groups were determined on the basis of median expression for all ER-positive breast tumors. p Value represents uncorrected log-rank test for low vs
high WNT4 expression. METABRIC Molecular Taxonomy of Breast Cancer International Consortium, TCGA The Cancer Genome Atlas
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is clearly multifaceted, as siCDKN1A only partially res-
cued the growth suppression by siWNT4 (Fig. 6c). Identi-
fication of additional WNT4 target genes in ILC, as well
as the WNT4 receptor and downstream signaling compo-
nents, is a critical future direction for research.
Understanding the mechanism by which WNT4 acti-
vates its signaling cascade (i.e., in an autocrine vs para-
crine mechanism) is an important future direction for
research. A key observation from Wnt4-transgenic mice
mammary gland studies was that though Wnt4 knockout
ablated ductal elongation and branching [10], the con-
verse was not true; Wnt4 overexpression did not induce
hyperplasia or tumorigenesis [29]. However, researchers
in an earlier study did observe that Wnt4 overexpression
induced mammary hyperplasia [60], and, taken together,
these studies highlight the potential importance of the
specific cell population expressing Wnt4 (discussed in
[29]). Interestingly, studies that have demonstrated
the role of Wnt4 in maintenance of the progenitor cell
niche [11–13] clearly showed a paracrine role for Wnt4,
wherein PR-positive, Wnt4-expressing cells secrete
Wnt4 to activate signaling in neighboring hormone
receptor-negative cells. Additionally, regulation of Wnt4
may be modified during pregnancy, wherein E2 and P4
may cooperate to induce paracrine Wnt4 signaling [61].
It is unclear whether similar mechanisms may be main-
tained in ILC cells, whether ILC-derived WNT4 can
signal in a paracrine mechanism with the tumor
microenvironment, or whether WNT4 operates in a
cell-autonomous vs nonautonomous manner to drive
proliferation of tumor cells.
Studies examining endocrine resistance mechanisms
specifically in ILC are in their infancy [1, 62]. Beyond
our LTED models, only one other ILC acquired endo-
crine resistance model has been characterized: SUM44/
LCCTam, which is a tamoxifen-resistant variant of
44PE [63]. Intriguingly, WNT4 is among the top 50 dif-
ferentially expressed genes between LCCTam and 44PE
(upregulated more than twofold in LCCTam vs 44PE
[GEO:GSE12708]), suggesting that WNT4 may be a
common mechanism of acquired endocrine resistance
in ILC cells. We further characterized WNT4-mediated
endocrine resistance in ILC-LTED and identified that
WNT4 signaling is maintained via activation of NF-kB
signaling in 134:LTED. Activation of NF-kB is a driver
of antiestrogen resistance in MCF-7 models of acquired
[64], Akt-driven [65], and HER2-driven [66] resistance.
In these contexts, ER is a repressor of NF-kB activity
[67], and loss of canonical ER activity (and parallel loss
of chicken ovalbumin upstream promoter transcription
factor II [68]) leads to reactivation of NF-kB. This in-
verse correlation between ER and NF-kB activity has
also been observed in patient tumor samples (reviewed
by Sas et al. [69]). However, it does not appear that NF-kB
activity is downstream of ER in ILC cells, as ICI treatment
had minimal or no effect on reporter output in ILC paren-
tal or LTED cells (Fig. 5a). Thus, though NF-kB may be a
shared endocrine resistance mechanism in breast cancers,
the mechanism of activation and potentially its signaling
may differ in IDC vs ILC. The presence of NF-kB/Rel
binding sites at the WNT4 ERBS (Additional file 10:
Figure S9b) suggests that WNT4 may be a direct target of
NF-kB signaling in ILC, and future studies will elucidate
the context required for NF-kB to regulateWNT4.
The increased expression of WNT4 in ER-positive
breast tumors is consistent with the role of WNT4 in me-
diating hormone response in the normal mammary gland,
and with our observations regarding the role of WNT4
in endocrine response in ILC cells. Though we ob-
served ER regulation of WNT4 specifically in ILC cells,
the association of WNT4 expression with PR status
across ER-positive tumors suggests that PR may regulate
WNT4 in IDC, as we observed in T47D cells, or that
WNT4 may be a marker of functional ER signaling. Im-
portantly, the expression data currently available represent
static, pretreatment measurement of WNT4 expression in
breast tumors; regulation of WNT4 expression following
endocrine therapy may be a superior biomarker for ILC
biology. Though gene expression data from ILC tumors
following neoadjuvant letrozole therapy have been re-
ported [70], the expression of many ILC-specific ER target
genes [8], including WNT4, were excluded from the ana-
lyses due to issues related to the use of multiple expres-
sion platforms. Future analyses of WNT4 regulation may
be possible on the basis of ongoing studies such as
POETIC [71] or our neoadjuvant trial for patients with
ILC (ClinicalTrials.gov identifier NCT02206984 [72]).
Conclusions
Recent clinical and laboratory studies suggest that
despite biomarkers consistent with favorable response to
endocrine therapy, ILC cells may use unique ER signaling
pathways to mediate endocrine response and resistance.
We have identified the Wnt ligand WNT4 as a novel, crit-
ical effector of ER signaling in ILC cells, which co-opt a
PR-driven developmental pathway by placing it under dir-
ect ER control. ER regulation of WNT4 correlates with
use of an ERBS at the WNT4 locus specifically in ILC
cells. Novel endocrine-resistant ILC-LTED models either
maintain ER function and WNT4 regulation or uncouple
WNT4 from ER and upregulate WNT4 expression. Acti-
vated NF-kB signaling can drive this upregulation of
WNT4 in ILC-LTED cells. In both ILC and ILC-LTED
cells, WNT4 suppresses CDKN1A/p21, which is critical
for maintenance of ILC cell proliferation. Knockdown of
CDKN1A can partially reverse the effects of siWNT4.
Taken together, these observations demonstrate that
WNT4 drives a critical signaling pathway in mediating
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endocrine response and resistance in ILC. Future studies
will examine the mechanisms leading to ER control of
WNT4 expression, elucidate the components of the
WNT4 signaling pathway, and evaluate the role of this
pathway in tumor models systems including patient-
derived xenografts and primary tumor tissue explants.
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Additional file 1: Figure S1. WNT4 is a putative direct ER target gene
in ILC cells. A schematic of WNT4 ERBS is shown. ER binding at WNT4
was observed in MM134, but not in IDC cells [73]. Sequence of predicted
EREs (red star) is shown vs consensus ERE. Red letters represent a match
with consensus. MM134 ChIP-seq data are derived from the study by
Sikora et al. [8]. MACS Model-based analysis of ChIP-Seq. (PDF 149 kb)
Additional file 2: Sequence and product information for oligos used in
this study. (XLSX 11 kb)
Additional file 3: Figure S2. Extent of WNT4 knockdown correlates
with effect of cell proliferation. MM134 cells were reverse-transfected with
increasing concentrations of MISSION siWNT4 pool (Sigma-Aldrich) or
siGENOME siWNT4 pool (GE Dharmacon, Lafayette, CO, USA) or were
treated with 1 μM ICI. Ctrl, Nontransfected; Rgt, Reagent-only (mock)-
transfected. RNA was harvested 48 h posttransfection, and proliferation
was assessed 6 days posttransfection. In each case, data are normalized
to Ctrl (100 %) and ICI-treated (0 %). (PDF 89 kb)
Additional file 4: Figure S3. SUM44/F has improved endocrine
response vs 44PE. SUM44/F cells were derived from 44PE as described in
the Methods section. Each line was hormone-deprived prior to treatment
with vehicle (0.1 % EtOH) or increasing concentrations of E2. Proliferation
was assessed 6 days posttreatment. Growth is shown as fold change vs
vehicle control. (PDF 87 kb)
Additional file 5: Figure S4. ER regulation of WNT4 and potential
interaction with PR at binding sites near the WNT4 gene locus. a MM330
cells were hormone-deprived as described in Materials and Methods and
treated with 1 nM E2 ± 1 μM ICI for 24 h. Bars represent biological tripli-
cate ± SD. *p < 0.05 by one-way analysis of variance vs respective control
with Dunnett’s multiple comparisons test. b Data derived from the study
by Mohammed et al. [27] [GEO:GSE68355]. Model-based analysis of ChIP-
Seq (MACS) peaks were visualized using the Integrated Genomics Viewer
browser (Broad Institute, Cambridge, MA, USA), and aligned the RefSeq
gene set in hg19. Dashed green box is an enlargement showing binding
sites proximal to the WNT4 ERBS in MM134 and the WNT4 transcriptional
start site. Dashed blue box shows an upstream region (−30 kb) of P4-
induced ER/PR binding in MCF-7. c Samples were treated and ChIP-qPCR
performed as described in Fig. 2 legend. IgG Immunoglobulin G. (PDF 175 kb)
Additional file 6: Figure S5. Establishment of long-term estrogen-de-
prived variants of ILC cell lines. a Schematic representation of
development of LTED lines together with representative phase-contrast
images (original magnification × 100) of resulting lines. b Once established
(i.e., able to be passaged routinely in T75 flasks), lysates were collected
from LTED lines, parental ILC cells, and MCF-7 cells. Immunoblotting
was performed as described in the Methods section. c Endocrine response
was assessed in ILC-LTED vs hormone-deprived parental cells. BCCL
cells were treated as indicated, and proliferation was assessed 6 days
after treatment. Proliferation is shown as baseline subtracted vs vehicle
(0.01 % EtOH) treatment. *p < 0.05 treatment vs vehicle control (t test).
+Immediately after establishment, 134:L/B maintained modest endocrine
responsiveness, but within several passages this was lost. Repeat experiments
revealed no difference between treatment and vehicle. IMEM Improved
minimal essential medium. (PDF 198 kb)
Additional file 7: Figure S6. ER and FGFR signaling in ILC-LTED cells.
a BCCL cells were treated and processed as described in the Fig. 3 legend.
Bars represent mean of biological triplicate ± SD. *p < 0.05 for vehicle control
vs ICI (t test). “E2 status” denotes the hormone status of the experimental
culture medium. +FBS-containing medium; −CSS-containing medium.
b ILC-LTED cells were reverse-transfected with 10 nM siSCR or
siWNT4 and allowed to attached overnight; cells were then treated
with increasing concentrations of FGFR inhibitor PD173074. Growth
was assessed 4 days and 5 days posttreatment for 134:L/E and 44:L/A,
respectively. (PDF 113 kb)
Additional file 8: Figure S7. β-Catenin dysfunction leads to lack of
canonical Wnt signaling in ILC cells. a Reverse-phase protein array
data derived from TCGA were extracted from the cBioPortal for Cancer
Genomics. b HT1080 (Wnt-responsive fibrosarcoma cells [33]) or MM134
cells were cotransfected with TOPFlash and Renilla luciferase reporter
plasmids, along with the indicated WNT plasmid or enhanced green
fluorescent protein (EGFP). EGFP plasmid was included at 5 % of plasmid
mass in all transfections to allow for visual confirmation of transfection.
Twenty-four hours posttransfection, lysates were harvested for luciferase
detection. RLU represent fold change vs EGFP cotransfection control. Bars
represent mean of biological triplicate ± SD. c Parental HT1080 cells
and HT1080-expressing WNT4 were assayed for DVL activation by
immunoblotting. The size shifts of DVL2/3 are consistent with protein
phosphorylation and Wnt signaling activation [33]. (PDF 128 kb)
Additional file 9: Figure S8. Cignal 45-Reporter Array identifies activated
signaling pathways in ILC-LTED cells. Transcription factor reporter arrays
were performed as described in the Methods section. Luciferase output is
shown as raw RLU. Dashed lines at −6 are for visual reference only. <p < 0.05
for vehicle vs ICI (t test); −not significant. xp < 0.05 for LTED vs parental
(for vehicle-treated) (t test). Note that statistical tests were not corrected
for multiple comparisons in this experiment, owing to the hypothesis-
generating nature of this semibiased screen. (PDF 153 kb)
Additional file 10: Figure S9. NF-kB signaling in ILC-LTED drives
WNT4-CDKN1A regulation. a Left, BCCL cells were treated with increasing
concentrations of BMS-345541. Proliferation was assessed 6 days after
treatment, shown as fold change vs vehicle (0.1 % dimethyl sulfoxide)
control. *p < 0.0001 for parental vs LTED proliferation at 10 μM BMS
(t test). Right, BCCL cells were treated with increasing concentrations of
BMS. Lysates were collected 48 h posttreatment. Differential sensitivity to
growth suppression at 10 μM BMS correlates with ablation of p-p65 at
this concentration. b Schematic of WNT4 ERBS indicating location and
sequence of predicted NF-kB/Rel binding sites. Consensus RELA (p65)
and NFKB1 binding sites are shown for reference. c 134:L/E cells were
reverse-transfected with 10 nM siRNA (individual constructs; numbers
reference those shown in Additional file 2), and RNA was collected
60 h posttransfection. Bars represent the mean of biological triplicate ± SD.
*p < 0.05 by ANOVA for expression vs siSCR (Dunnett’s multiple comparisons
test). d MM134 cells were reverse-transfected with 10 nM siWNT4 or treated
with 1 μM IWR or 10 μM JW for 24 h. Bars represent biological triplicate ±
SD. *p < 0.05 by ANOVA (Dunnett’s multiple comparisons test) vs control.
e MCF-7 and HCC1428 cells were treated and processed as described in the
Fig. 5e legend. ILC and ILC-LTED data are reproduced from Fig. 5e. Data are
normalized to siSCR control knockdown. (PDF 218 kb)
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